CAJ | 학술논문

目的：探讨脂康颗粒联合非诺贝特治疗高脂血症的临床疗效及安全性。方法将76例高脂血症患者随机分为试验组和对照组。试验组予以脂康颗粒联合非诺贝特治疗，对照组予以非诺贝特及安慰剂治疗。非诺贝特200 mg 1/日，脂康颗粒及安慰剂用量为8 g，2/日，两组均连续用药8周。观察两组治疗前后血脂变化、总有效率及不良反应等。结果治疗后患者总胆固醇、三酰甘油及低密度脂蛋白胆固醇下降幅度均高于对照组（P＜0.05），高密度脂蛋白胆固醇上升幅度也高于对照组（P＜0.05）。试验组降脂总有效率为92.3%，明显高于对照组（75.7%），差异有统计学意义（P＜0.05）。治疗后试验组丙氨酸氨基转移酶及天冬氨酸氨基转移酶水平均较治疗前明显降低（P＜0.05），对照组无明显变化（P＞0.05）。结论脂康颗粒联合非诺贝特治疗高脂血症，不仅有协同降脂作用，还具有保肝降酶的疗效。
목적：탐토지강과립연합비낙패특치료고지혈증적림상료효급안전성。방법장76례고지혈증환자수궤분위시험조화대조조。시험조여이지강과립연합비낙패특치료，대조조여이비낙패특급안위제치료。비낙패특200 mg 1/일，지강과립급안위제용량위8 g，2/일，량조균련속용약8주。관찰량조치료전후혈지변화、총유효솔급불량반응등。결과치료후환자총담고순、삼선감유급저밀도지단백담고순하강폭도균고우대조조（P＜0.05），고밀도지단백담고순상승폭도야고우대조조（P＜0.05）。시험조강지총유효솔위92.3%，명현고우대조조（75.7%），차이유통계학의의（P＜0.05）。치료후시험조병안산안기전이매급천동안산안기전이매수평균교치료전명현강저（P＜0.05），대조조무명현변화（P＞0.05）。결론지강과립연합비낙패특치료고지혈증，불부유협동강지작용，환구유보간강매적료효。
Objective To investigate the clinical efficacy and safety of Zhikang Granules combining fenofibrate in patients with hyperlipidemia. Methods The patients (n=76) were randomly divided into test group and control group. The test group was given Zhikang Granules (8 g twice a day) combining fenofibrate (200 mg once a day) and control group was given fenofibrate (200 mg once a day) and placebo (8 g twice a day) for 8 w. The changes of blood fat, total effective rate and adverse reactions were observed in 2 groups. Results The decrease degree of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein-cholesterol (LDL-C) was higher (P<0.05) and increase degree of high-density lipoprotein-cholesterol (HDL-C) was higher (P<0.05) in test group than those in control group. The total effective rate was 92.3%in test group and 75.7%in control group (P<0.05). After treatment, ALT and AST decreased significantly in test group (P<0.05) and had no significant changes in control group (P>0.05). Conclusion Zhikang Granules combining fenofibrate has not only cooperative effect of reducing blood fat, but also curative effect of protecting liver and lowering transaminase in the treatment of hypertension.